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Any study of myeloproliferative neoplasms (MPNs)
that lacks adequate clinical input is doomed to cause
diagnostic uncertainty and increased controversy. In the
paper by Buhr et al. published in Haematologica,1 the
authors studied 102 cases of essential thrombocythemia
(ET) and early primary myelofibrosis (PMF) by comparing
clinical criteria with the histopathological evaluation
independently performed by 6 hematopathologists.
According to the World Health Organization (WHO)
classification, the minor clinical criteria for PMF include
leukoerythroblastosis, increase in serum lactate dehydro-
genase (LDH) level, anemia, and splenomegaly.2,3 As
explicitly stated in the WHO guidelines, the degree of
abnormalities can be borderline or marked, and the pres-
ence of at least two of these criteria is required for diag-
nosis.2,4 In the work Buhr et al., “Design and Methods”
and Table 1 confirm that the authors failed to define “bor-
derline values” (e.g. presence of circulating myeloid pre-
cursors and erythroblasts > 1%, borderline elevated LDH
according to local threshold values, anemia defined as
hemoglobin <13 g/dL in men or <12 g/dL in women, as
well as palpable splenomegaly as > 1 cm below costal
margin). Moreover, as shown in Table 2 in the same
paper, a considerable number of cases lacked clinical data
altogether. Therefore, we would not reach the conclusion
“that more than 50% of PMF cases became MPNs unclas-
sifiable when WHO criteria were applied“. Since no
ranges of hemoglobin or hematocrit results were provid-
ed by the authors, a significant proportion of cases within
their ET cohort may in fact represent initial polycythemia
vera (PV), clinically mimicking ET.5,6 The inadvertent
inclusion of early PV cases would have seriously compro-
mised the analysis and be responsible for unclassifiable
cases. 
The inadequacy of the study becomes even more evi-
dent when its results are compared and contrasted with
those obtained in a much larger cohort of patients with
ET or PMF, in which clinical and morphological parame-
ters were independently collected by a combined clinico-
pathological team.7 The authors’ conclusion that none of
the 646 cases with early PMF described in the latter study
had leukoerythroblastosis is incorrect, because only
median values for myeloid precursors and erythroblasts
were reported.7 In fact, the range for myeloblasts was up
to 4% (mean 0.05%) and that for erythroblasts up to
14% (mean 0.21%), respectively. 
In the same study, no information is provided in rela-
tion to the length of disease history antedating the exam-
ined biopsy. If the biopsy was not obtained at disease
onset or in close proximity to such a time, it might show
changes related to disease progression that may render
the case truly unclassifiable. In addition, WHO criteria
can only be applied to untreated patients.2,3 However, no
corresponding information is provided in this paper.
Concerning previously published studies, a totally
blinded evaluation of 295 patients, clinically considered
to represent either ET or possibly early PMF, performed
in two distinct pathology departments revealed an over-
all concordance of 78% with an interobserver reliability
of kappa=0.626 (P=0.001), a finding which finds substan-
tial consensus.7 The high concordance in that study, in
contrast with what is claimed in the paper by Buhr et al.,1
was obtained in the absence of any prior consensus con-
ference or training. On the other hand, after such a con-
sensus meeting between pathologists and clinicians, the
concordance in the final clinical diagnosis was 82% for
the total cohort and 93% for the prevalent group of ET
versus early PMF patients (kappa=0.740; P=0.001), i.e.
substantial agreement.7 Moreover, the authors cited but
failed to recognize the importance of a clinicopathologi-
cal study on 1,104 treatment-naive patients diagnosed
independently by seven international centers as being
consistent with ET according to the WHO guidelines.8 A
review of the initial bone marrow specimens confirmed
the ET diagnosis in 81% (890 patients) and was revised
to early PMF in only 16% (180 patients). A critical analy-
sis regarding the shortcomings of the study by Wilkins
and co-workers,9 as previously stressed,10 is also missing.
In another cited study,11 the authors claimed to diagnose
ET strictly according to the WHO guidelines but
described minor to moderate reticulin fibrosis in more
than 50% of their patients, which is definitively inconsis-
tent with the WHO criteria.2,3
The erroneous proposal to replace the WHO classifica-
tion by a scheme focused on fiber grading (ET grades 1 to
3) includes as first end point “true” ET without increase
in reticulin but fails to recognize early (initial) PMF with
fiber grade 0. This classification groups together ET, early
PMF and overt PMF, and is not compatible with a previ-
ous study of the first and last author speaking in favor of
pre-fibrotic PMF.12
Regarding the estimated intra- (reproducibility) and
inter- (consensus) observer concordance, striking differ-
ences between the panelists are outlined in Table 4. In
particular, a significant variability in intra-rater reliability
ranging from 0.25 to 0.78 is observed which might prob-
ably reflect the varying degrees of experience with the
WHO classification by some of the panelists (panelists
P1, P2, P5, and P6 with kappa values between 0.60 and
0.78 (mean 0.71) compatible with substantial repro-
ducibility contrasting with panelists P3 with a kappa of
0.25 and P4 with 0.55 indicating only a poor intra-rater
repeatability). Furthermore, the presented approach to
measure the interobserver consensus does not make full
use of the original data, and will usually not yield the
same values as that obtained from a true multi-rater
measure of agreement. To allow comparison with previ-
ous studies, unweighted and weighted values of kappa,
together with the 95% confidence intervals of the values,
should have been estimated.
Finally, the title of the paper by Buhr et al. would sug-
gest to the non-informed reader that it may represent the
opinion of the European Bone Marrow Working Group
(EBMWG). In reality, the study design and methodology
was never fully discussed at EBMWG meetings. The
results obtained on a limited database of heterogeneously
selected cases lacking adequate clinical correlates most
definitely represent a non-consensus based conclusion.
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